Piperacillin-tazobactam - Revision history

Aidan at 15:07, 9 January 2024

2024-01-09T15:07:10Z

@@ Line 71: / Line 71: @@
 |Gram-positive bacteria
 | colspan="7" |susceptibility predicted by [[penicillin]]
 |}
 [[Category:Β-lactams]]

Aidan: Text replacement - " species]]" to "]]"

2022-02-08T02:53:22Z

Text replacement - " species]]" to "]]"

← Older revision		Revision as of 02:53, 8 February 2022
Line 33:		Line 33:
	\|≤14		\|≤14
	\|-		\|-
	\|[[Acinetobacter ~~species~~]]		\|[[Acinetobacter]]
	\|		\|
	\|≤16/4		\|≤16/4

Aidan at 15:25, 13 September 2020

2020-09-13T15:25:12Z

← Older revision		Revision as of 15:25, 13 September 2020
Line 1:		Line 1:
	== Background ==		==Background==

	=== Clinical Breakpoints ===		===Clinical Breakpoints===
	{\| class="wikitable"		{\| class="wikitable"
	! rowspan="2" \|Species		! rowspan="2" \|Species
	! rowspan="2" \|ECV (μg/mL)		! rowspan="2" \|ECV (μg/mL)
	! colspan="4" \|Breakpoints (μg/mL)		! colspan="3" \|Breakpoints (μg/mL)
	! colspan="4" \|Breakpoints (mm)		! colspan="3" \|Breakpoints (mm)
	\|-		\|-
	!S		!S
	!I		!I
	!SDD
	!R		!R
	!S		!S
	!I		!I
	!SDD
	!R		!R
	\|-		\|-
Line 21:		Line 19:
	\|≤16/4		\|≤16/4
	\|32/4-64/4		\|32/4-64/4
	\|—
	\|≥128/4		\|≥128/4
	\|≥21		\|≥21
	\|18-20		\|18-20
	\|—
	\|≤17		\|≤17
	\|-		\|-
Line 32:		Line 28:
	\|≤16/4		\|≤16/4
	\|32/4-64/4		\|32/4-64/4
	\|—
	\|≥128/4		\|≥128/4
	\|≥21		\|≥21
	\|15-20		\|15-20
	\|—
	\|≤14		\|≤14
	\|-		\|-
Line 43:		Line 37:
	\|≤16/4		\|≤16/4
	\|32/4-64/4		\|32/4-64/4
	\|—
	\|≥128/4		\|≥128/4
	\|≥21		\|≥21
	\|18-20		\|18-20
	\|—
	\|≤17		\|≤17
	\|-		\|-
Line 54:		Line 46:
	\|≤16/4		\|≤16/4
	\|32/4-64/4		\|32/4-64/4
	\|—
	\|≥128/4		\|≥128/4
	\|
	\|		\|
	\|		\|
Line 65:		Line 55:
	\|≤16/4		\|≤16/4
	\|32/4-64/4		\|32/4-64/4
	\|—
	\|≥128/4		\|≥128/4
	\|
	\|		\|
	\|		\|
Line 75:		Line 63:
	\|		\|
	\|≤1/4		\|≤1/4
	\|—
	\|—		\|—
	\|≥2/4		\|≥2/4
	\|≥21		\|≥21
	\|—
	\|—		\|—
	\|—		\|—
	\|-		\|-
	\|Gram-positive bacteria		\|Gram-positive bacteria
	\| colspan="9" \|susceptibility predicted by [[penicillin]]		\| colspan="7" \|susceptibility predicted by [[penicillin]]
	\|}		\|}
	[[Category:Β-lactams]]		[[Category:Β-lactams]]

Aidan: Created page with "== Background == === Clinical Breakpoints === {| class="wikitable" ! rowspan="2" |Species ! rowspan="2" |ECV (μg/mL) ! colspan="4" |Breakpoints (μg/mL) ! colspan="4" |Break..."

2020-09-10T14:52:54Z

Created page with "== Background == === Clinical Breakpoints === {| class="wikitable" ! rowspan="2" |Species ! rowspan="2" |ECV (μg/mL) ! colspan="4" |Breakpoints (μg/mL) ! colspan="4" |Break..."

New page

== Background ==

=== Clinical Breakpoints ===
{| class="wikitable"
! rowspan="2" |Species
! rowspan="2" |ECV (μg/mL)
! colspan="4" |Breakpoints (μg/mL)
! colspan="4" |Breakpoints (mm)
|-
!S
!I
!SDD
!R
!S
!I
!SDD
!R
|-
|[[Enterobacterales]]
|
|≤16/4
|32/4-64/4
|—
|≥128/4
|≥21
|18-20
|—
|≤17
|-
|[[Pseudomonas aeruginosa]]
|
|≤16/4
|32/4-64/4
|—
|≥128/4
|≥21
|15-20
|—
|≤14
|-
|[[Acinetobacter species]]
|
|≤16/4
|32/4-64/4
|—
|≥128/4
|≥21
|18-20
|—
|≤17
|-
|Other non-Enterobacterales
|
|≤16/4
|32/4-64/4
|—
|≥128/4
|
|
|
|
|-
|[[Anaerobes]]
|
|≤16/4
|32/4-64/4
|—
|≥128/4
|
|
|
|
|-
|[[Haemophilus influenzae]] and [[Haemophilus parainfluenzae]]
|
|≤1/4
|—
|—
|≥2/4
|≥21
|—
|—
|—
|-
|Gram-positive bacteria
| colspan="9" |susceptibility predicted by [[penicillin]]
|}
[[Category:Β-lactams]]
[[Category:Β-lactamase inhibitors]]